Metastasis-directed therapy in prostate cancer: Why, when, and how?

Ryan M. Phillips, Matthew P. Deek, Theodore L. DeWeese, Phuoc T. Tran

Research output: Contribution to journalReview articlepeer-review

Abstract

Metastatic prostate cancer remains a life-limiting disease; while we have seen significant advances in systemic approaches which form the backbone of management, no curative paradigm yet exists. Metastasis-directed therapy (MDT) with stereotactic ablative radiotherapy (SABR) has emerged as a promising complementary technique for the management of low-volume metastatic prostate cancer. Herein we will review the rationale, potential benefits, and practical considerations associated with this approach.

Original languageEnglish (US)
Pages (from-to)394-399
Number of pages6
JournalONCOLOGY (United States)
Volume33
Issue number10
StatePublished - 2019

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Metastasis-directed therapy in prostate cancer: Why, when, and how?'. Together they form a unique fingerprint.

Cite this